Blurring the boundaries between regulatory approval and HTAs
This article was originally published in Scrip
Once there was a clear distinction between the scientific evaluation of new drugs and the assessment of their value for use in reimbursement decisions. The latter was often referred to as the “fourth hurdle”, and took place after quality, safety and efficacy had been assessed and the product approved. Now things are changing, though, and relative value assessments are becoming more closely allied to the drug approval process itself.
You may also be interested in...
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.
The UK’s rapid authorization of the Pfizer/BioNTech COVID-19 vaccine has sparked a public debate over regulatory processes at some of the world’s key regulatory bodies.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.